Meeting
2023 ASCO Annual Meeting
Evaluation of small extracellular vesicles as biomarkers of efficacy with anti-PD-1 mAb therapy in patients with recurrent/metastatic HNSCC.
Authors
Dan Paul Zandberg
UPMC Hillman Cancer Center, Pittsburgh, PA
Dan Paul Zandberg , Chang-Sook Hong , Andrew Swartz , Ronan Wenhan Hsieh , Jennifer Lynn Anderson , Robert L. Ferris , Brenda Diergaarde , Theresa L Whiteside
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6042)
DOI
10.1200/JCO.2023.41.16_suppl.6042
Abstract #
6042
Poster Bd #
34
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma.
First Author: Mark Chang
First Author: Susanna Swoboda
Poster
2023 ASCO Annual Meeting
Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.
First Author: Ezra E.W. Cohen
Poster
2018 ASCO Annual Meeting
CD8 and PD-L1 determination in lung tumor tissue as prognostic biomarker and a predictive marker of anti PD-1 efficacy.
First Author: Jean-David Fumet